Deciphering the role of n-3 polyunsaturated fatty acid-derived lipid mediators in health and disease

Proceedings of the Nutrition Society

Volumn 72, Issue 4, 2013, Pages 441-450

  Spite, Matthew ^a  

^a University of Louisville School of Medicine   (United States)

Author keywords

DHA; EPA; Resolution of inflammation; Resolvins

Indexed keywords

CD59 ANTIGEN; G PROTEIN COUPLED RECEPTOR; LEUKOTRIENE; MARESIN; OMEGA 3 FATTY ACID; PROSTAGLANDIN; RESOLVIN; UNCLASSIFIED DRUG; ARACHIDONIC ACID; AUTACOID; BIOLOGICAL FACTOR; CYCLOOXYGENASE 2; DOCOSAHEXAENOIC ACID; FORMYLPEPTIDE RECEPTOR LIKE 1; ICOSAPENTAENOIC ACID; LEUKOTRIENE B4; LIPID; LIPOXIN A; LIPOXYGENASE; OMEGA 6 FATTY ACID; POLYUNSATURATED FATTY ACID; PROSTAGLANDIN SYNTHASE; PROSTANOID;

CONFERENCE PAPER; DISEASE COURSE; HOST RESISTANCE; HUMAN; INFLAMMATION; LIPOGENESIS; MEDIATOR; NONHUMAN; SYMPOSIUM; TARGET CELL; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; BIOSYNTHESIS; CLINICAL STUDY; DISEASE MODEL; DISEASES; HEALTH;

DOCOSAHEXAENOIC ACIDS; FATTY ACIDS, OMEGA-3; HUMANS; IMMUNOMODULATION; INFLAMMATION; INFLAMMATION MEDIATORS; LIPID METABOLISM; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84893089131     PISSN: 00296651     EISSN: 14752719     Source Type: Journal    
DOI: 10.1017/S0029665113003030     Document Type: Conference Paper

References (78)

1. Burr GO & Burr MM (1973) Nutrition classics from The Journal of Biological Chemistry 82:345-67, 1929. A new deficiency disease produced by the rigid exclusion of fat from the diet. Nutr Rev 31, 248-249.
2. Le HD, Meisel JA, de Meijer VE, et al. (2009) The essentiality of arachidonic acid and docosahexaenoic acid. Prostaglandins Leukot Essent Fatty Acids 81, 165-170.
3. Fritsche K (2006) Fatty acids as modulators of the immune response. Annu Rev Nutr 26, 45-73.
4. Harbige LS (2003) Fatty acids, the immune response, and autoimmunity: A question of n-6 essentiality and the balance between n-6 and n-3. Lipids 38, 323-341.
5. Samuelsson B, Dahlen SE, Lindgren JA, et al. (1987) Leukotrienes and lipoxins: Structures, biosynthesis, and biological effects. Science 237, 1171-1176.
6. Serhan CN, Chiang N & Van Dyke TE (2008) Resolving inflammation: Dual anti-inflammatory and pro-resolution lipid mediators. Nat Rev Immunol 8, 349-361.
7. London B, Albert C, Anderson ME, et al. (2007) Omega-3 fatty acids and cardiac arrhythmias: Prior studies and recommendations for future research: A report from the National Heart, Lung, and Blood Institute and Office Of Dietary Supplements Omega-3 Fatty Acids and their Role in Cardiac Arrhythmogenesis Workshop. Circulation 116, e320-e335.
8. Calder PC (2013) Omega-3 polyunsaturated fatty acids and inflammatory processes: Nutrition or pharmacology? Br J Clin Pharmacol 75, 645-662.
9. Sprecher H (2000) Metabolism of highly unsaturated n-3 and n-6 fatty acids. Biochim Biophys Acta 1486, 219-231.
10. Hudert CA, Weylandt KH, Lu Y, et al. (2006) Transgenic mice rich in endogenous omega-3 fatty acids are protected from colitis. Proc Natl Acad Sci USA 103, 11276-11281.
11. Connor KM, SanGiovanni JP, Lofqvist C, et al. (2007) Increased dietary intake of omega-3-polyunsaturated fatty acids reduces pathological retinal angiogenesis. Nat Med 13, 868-873.
12. Xia S, Lu Y, Wang J, et al. (2006) Melanoma growth is reduced in fat-1 transgenic mice: Impact of omega-6/ omega-3 essential fatty acids. Proc Natl Acad Sci USA 103, 12499-12504.
13. DeFilippis AP & Sperling LS (2006) Understanding omega-3's. Am Heart J 151, 564-570.
14. Thies F, Garry JM, Yaqoob P, et al. (2003) Association of n-3 polyunsaturated fatty acids with stability of atherosclerotic plaques: A randomised controlled trial. Lancet 361, 477-485.
15. De Caterina R (2011) n-3 fatty acids in cardiovascular disease. N Engl J Med 364, 2439-2450.
16. GISSI-prevenzione Investigators (1999) Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: Results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. Lancet 354, 447-455.
17. Tavazzi L, Maggioni AP, Marchioli R, et al. (2008) Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): A randomised, doubleblind, placebo-controlled trial. Lancet 372, 1223-1230.
18. Samuelsson B (2012) Role of basic science in the development of new medicines: Examples from the eicosanoid field. J Biol Chem 287, 10070-10080.
19. Capdevila JH, Harris RC & Falck JR (2002) Microsomal cytochrome P450 and eicosanoid metabolism. Cell Mol Life Sci 59, 780-789.
20. Hata AN & Breyer RM (2004) Pharmacology and signaling of prostaglandin receptors: Multiple roles in inflammation and immune modulation. Pharmacol Ther 103, 147-166.
21. Serhan CN & Petasis NA (2011) Resolvins and protectins in inflammation resolution. Chem Rev 111, 5922-5943.
22. Zhang MJ & Spite M (2012) Resolvins: Anti-inflammatory and proresolving mediators derived from omega-3 polyunsaturated fatty acids. Annu Rev Nutr 32, 203-227.
23. Serhan CN, Clish CB, Brannon J, et al. (2000) Novel functional sets of lipid-derived mediators with antiinflammatory actions generated from omega-3 fatty acids via cyclooxygenase 2-nonsteroidal antiinflammatory drugs and transcellular processing. J Exp Med 192, 1197-1204.
24. Serhan CN, Hong S, Gronert K, et al. (2002) Resolvins: A family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals. J Exp Med 196, 1025-1037.
25. Arita M, Bianchini F, Aliberti J, et al. (2005) Stereochemical assignment, antiinflammatory properties, and receptor for the omega-3 lipid mediator resolvin E1. J Exp Med 201, 713-722.
26. Arita M, Clish CB & Serhan CN (2005) The contributions of aspirin and microbial oxygenase to the biosynthesis of anti-inflammatory resolvins: Novel oxygenase products from omega-3 polyunsaturated fatty acids. Biochem Biophys Res Commun 338, 149-157.
27. Oh SF, Pillai PS, Recchiuti A, et al. (2011) Pro-resolving actions and stereoselective biosynthesis of 18S E-series resolvins in human leucocytes and murine inflammation. J Clin Invest 121, 569-581.
28. Oh SF, Dona M, Fredman G, et al. (2012) Resolvin E2 formation and impact in inflammation resolution. J Immunol 188, 4527-4534.
29. Tjonahen E, Oh SF, Siegelman J, et al. (2006) Resolvin E2: Identification and anti-inflammatory actions: Pivotal role of human 5-lipoxygenase in resolvin E series biosynthesis. Chem Biol 13, 1193-1202.
30. Isobe Y, Arita M, Matsueda S, et al. (2012) Identification and structure determination of novel anti-inflammatory mediator resolvin E3, 17,18-dihydroxyeicosapentaenoic acid. J Biol Chem 287, 10525-10534.
31. Spite M & Serhan CN (2010) Novel lipid mediators promote resolution of acute inflammation: Impact of aspirin and statins. Circ Res 107, 1170-1184.
32. Dalli J, Winkler JW, Colas RA, et al. (2013) Resolvin D3 and aspirin-Triggered resolvin D3 are potent immunoresolvents. Chem Biol 20, 188-201.
33. Hong S, Gronert K, Devchand PR, et al. (2003) Novel docosatrienes and 17S-resolvins generated from docosahexaenoic acid in murine brain, human blood, and glial cells. Autacoids in anti-inflammation. J Biol Chem 278, 14677-14687.
34. Marcheselli VL, Hong S, Lukiw WJ, et al. (2003) Novel docosanoids inhibit brain ischemia-reperfusion-mediated leucocyte infiltration and pro-inflammatory gene expression. J Biol Chem 278, 43807-43817.
35. Mukherjee PK, Marcheselli VL, Serhan CN, et al. (2004) Neuroprotectin D1: A docosahexaenoic acid-derived docosatriene protects human retinal pigment epithelial cells from oxidative stress. Proc Natl Acad Sci USA 101, 8491-8496.
36. Serhan CN, Gotlinger K, Hong S, et al. (2006) Anti-inflammatory actions of neuroprotectin D1/protectin D1 and its natural stereoisomers: Assignments of dihydroxy-containing docosatrienes. J Immunol 176, 1848-1859.
37. Chen P, Fenet B, Michaud S, et al. (2009) Full characterization of PDX, a neuroprotectin/protectin D1 isomer, which inhibits blood platelet aggregation. FEBS Lett 583, 3478-3484.
38. Serhan CN, Yang R, Martinod K, et al. (2009) Maresins: Novel macrophage mediators with potent antiinflammatory and proresolving actions. J Exp Med 206, 15-23.
39. Dalli J, Zhu M, Vlasenko NA, et al. (2013) The novel 13S,14S-epoxy- maresin is converted by human macrophages to maresin1 (MaR1), inhibits leukotriene A4 hydrolase (LTA4H), and shifts macrophage phenotype. FASEB J.
40. Serhan CN, Dalli J, Karamnov S, et al. (2012) Macrophage proresolving mediator maresin 1 stimulates tissue regeneration and controls pain. FASEB J 26, 1755-1765.
41. Buckley CD, Gilroy DW, Serhan CN, et al. (2013) The resolution of inflammation. Nat Rev Immunol 13, 59-66.
42. Serhan CN, Brain SD, Buckley CD, et al. (2007) Resolution of inflammation: State of the art, definitions and terms. FASEB J 21, 325-332.
43. Kang YJ, Mbonye UR, DeLong CJ, et al. (2007) Regulation of intracellular cyclooxygenase levels by gene transcription and protein degradation. Prog Lipid Res 46, 108-125.
44. Silverman ES & Drazen JM (1999) The biology of 5-lipoxygenase: Function, structure, and regulatory mechanisms. Proc Assoc Am Physicians 111, 525-536.
45. Conrad DJ, Kuhn H, Mulkins M, et al. (1992) Specific inflammatory cytokines regulate the expression of human monocyte 15-lipoxygenase. Proc Natl Acad Sci U S A 89, 217-221.
46. Ariel A, Li PL, Wang W, et al. (2005) The docosatriene protectin D1 is produced by TH2 skewing and promotes human T cell apoptosis via lipid raft clustering. J Biol Chem 280, 43079-43086.
47. Dalli J & Serhan CN (2012) Specific lipid mediator signatures of human phagocytes: Microparticles stimulate macrophage efferocytosis and pro-resolving mediators. Blood 120, e60-e72.
48. Chiang N, Fredman G, Backhed F, et al. (2012) Infection regulates pro-resolving mediators that lower antibiotic requirements. Nature 484, 524-528.
49. Morita M, Kuba K, Ichikawa A, et al. (2013) The lipid mediator protectin d1 inhibits influenza virus replication and improves severe influenza. Cell 153, 112-125.
50. Spite M, Norling LV, Summers L, et al. (2009) Resolvin D2 is a potent regulator of leucocytes and controls microbial sepsis. Nature 461, 1287-1291.
51. El Kebir D, Gjorstrup P & Filep JG (2012) Resolvin E1 promotes phagocytosis-induced neutrophil apoptosis and accelerates resolution of pulmonary inflammation. Proc Natl Acad Sci USA 109, 14983-14988.
52. Schwab JM, Chiang N, Arita M, et al. (2007) Resolvin E1 and protectin D1 activate inflammation-resolution programmes. Nature 447, 869-874.
53. Ariel A, Fredman G, Sun YP, et al. (2006) Apoptotic neutrophils and T cells sequester chemokines during immune response resolution through modulation of CCR5 expression. Nat Immunol 7, 1209-1216.
54. Campbell EL, Louis NA, Tomassetti SE, et al. (2007) Resolvin E1 promotes mucosal surface clearance of neutrophils: A new paradigm for inflammatory resolution. FASEB J 21, 3162-3170.
55. Krishnamoorthy S, Recchiuti A, Chiang N, et al. (2010) Resolvin D1 binds human phagocytes with evidence for proresolving receptors. Proc Natl Acad Sci USA 107, 1660-1665.
56. Ohira T, Arita M, Omori K, et al. (2010) Resolvin E1 receptor activation signals phosphorylation and phagocytosis. J Biol Chem 285, 3451-3461.
57. Gao L, Faibish D, Fredman G, et al. (2013) Resolvin E1 and chemokine-like receptor 1 mediate bone preservation. J Immunol 190, 689-694.
58. Dona M, Fredman G, Schwab JM, et al. (2008) Resolvin E1, an EPA-derived mediator in whole blood, selectively counter regulates leukocytes and platelets. Blood 112, 848-855.
59. Fredman G, Van Dyke TE & Serhan CN (2010) Resolvin E1 regulates adenosine diphosphate activation of human platelets. Arterioscler Thromb Vasc Biol 30, 2005-2013.
60. Arita M, Ohira T, Sun YP, et al. (2007) Resolvin E1 selectively interacts with leukotriene B4 receptor BLT1 and ChemR23 to regulate inflammation. J Immunol 178, 3912-3917.
61. Krishnamoorthy S, Recchiuti A, Chiang N, et al. (2012) Resolvin D1 receptor stereoselectivity and regulation of inflammation and proresolving microRNAs. Am J Pathol 180, 2018-2027.
62. Norling LV, Dalli J, Flower RJ, et al. (2012) Resolvin D1 limits polymorphonuclear leukocyte recruitment to inflammatory loci: Receptor-dependent actions. Arterioscler Thromb Vasc Biol 32, 1970-1978.
63. Marcheselli VL, Mukherjee PK, Arita M, et al. (2010) Neuroprotectin D1/protectin D1 stereoselective and specific binding with human retinal pigment epithelial cells and neutrophils. Prostaglandins Leukot Essent Fatty Acids 82, 27-34.
64. Tang Y, Zhang MJ, Hellmann J, et al. (2013) Proresolution therapy for the treatment of delayed healing of diabetic wounds. Diabetes 62, 618-627.
65. Bohr S, Patel SJ, Sarin D, et al. (2013) Resolvin D2 prevents secondary thrombosis and necrosis in a mouse burn wound model. Wound Repair Regen 21, 35-43.
66. Kurihara T, Jones CN, Yu YM, et al. (2013) Resolvin D2 restores neutrophil directionality and improves survival after burns. FASEB J 6, 2270-2281.
67. Norling LV, Spite M, Yang R, et al. (2011) Cutting edge: Humanized nano-proresolving medicines mimic inflammation-resolution and enhance wound healing. J Immunol 186, 5543-5547.
68. Claria J, Dalli J, Yacoubian S, et al. (2012) Resolvin D1 and resolvin D2 govern local inflammatory tone in obese fat. J Immunol 189, 2597-2605.
69. Claria J, Gonzalez-Periz A, Lopez-Vicario C, et al. (2011) New insights into the role of macrophages in adipose tissue inflammation and fatty liver disease: Modulation by endogenous omega-3 fatty acid-derived lipid mediators. Front Immunol 2, 49.
70. Claria J, Nguyen BT, Madenci A, et al. (2013) Diversity of lipid mediators in human adipose tissue depots. Am J Physiol Cell Physiol (In the Press).
71. Gonzalez-Periz A, Horrillo R, Ferre N, et al. (2009) Obesity-induced insulin resistance and hepatic steatosis are alleviated by omega-3 fatty acids: A role for resolvins and protectins. FASEB J 23, 1946-1957.
72. Mas E, Croft KD, Zahra P, et al. (2012) Resolvins D1, D2, and other mediators of self-limited resolution of inflammation in human blood following n-3 fatty acid supplementation. Clin Chem 58, 1476-1484.
73. Levy BD, Kohli P, Gotlinger K, et al. (2007) Protectin D1 is generated in asthma and dampens airway inflammation and hyperresponsiveness. J Immunol 178, 496-502.
74. Ho KJ, Spite M, Owens CD, et al. (2010) Aspirin-Triggered lipoxin and resolvin E1 modulate vascular smooth muscle phenotype and correlate with peripheral atherosclerosis. Am J Pathol 177, 2116-2123.
75. Sanak M, Levy BD, Clish CB, et al. (2000) Aspirin-Tolerant asthmatics generate more lipoxins than aspirin-intolerant asthmatics. Eur Respir J 16, 44-49.
76. Ji RR, Xu ZZ, Strichartz G, et al. (2011) Emerging roles of resolvins in the resolution of inflammation and pain. Trends Neurosci 34, 599-609.
77. Park CK, Xu ZZ, Liu T, et al. (2011) Resolvin D2 is a potent endogenous inhibitor for transient receptor potential subtype V1/A1, inflammatory pain, and spinal cord synaptic plasticity in mice: Distinct roles of resolvin D1, D2, and E1. J Neurosci 31, 18433-18438.
78. Xu ZZ, Zhang L, Liu T, et al. (2010) Resolvins RvE1 and RvD1 attenuate inflammatory pain via central and peripheral actions. Nat Med 16, 592-597.